Atea Pharmaceuticals, Inc.
Atea Pharmaceuticals, Inc. (AVIR) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
avir · stock forecast · 4 analysts (3M) · FMP · updated Jun 8, 2026
Analyst Rating & Consensus
Based on 4 Wall Street analysts in the past 3 months
Hold
4 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$10.00
Consensus
$10.00
+130.9% upside
Low
$10.00
Median: $10 · Last Close: $4.33
12-Month Price Target Forecast
Historical closing prices + analyst 12-month price target forecast cone
Short-Term Price Prediction
Low ActivityAlgorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-09 | $4.23 | ↓ 2.36% |
1-day model range: $4.15–$4.31. Peak: $4.31 (-2.36%).
Long-Term Stock Price Prediction
Annual stock price forecast · 2027 / 2028 / 2029 / 2030 / 2031
| Year | Avg Price | Change |
|---|---|---|
| 2027 | — | +6.5% |
| 2028 | — | +10.3% |
| 2029 | — | +12.4% |
| 2030 | — | +13.6% |
| 2031 | — | +14.3% |
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Insufficient Trading Activity — Sentiment Signals Disabled
This stock has very low trading volume (ZOMBIE condition). Sentiment analysis requires sufficient price action. RSI and MACD values below are still shown for reference.
Moving Averages · AVIR · Jun 8, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2026-03-09 | Evercore ISI Group | Maintains | Outperform→Outperform |
| 2025-04-11 | Morgan Stanley | Maintains | Equal Weight→Equal Weight |
| 2024-08-13 | Morgan Stanley | Upgrade ↑ | Underweight→Equal Weight |
| 2023-08-10 | JP Morgan | Downgrade ↓ | Neutral→Underweight |
| 2023-03-16 | JP Morgan | Maintains | Neutral→Neutral |
| 2023-01-27 | SVB Leerink | Maintains | Market Perform→Market Perform |
| 2023-01-24 | Morgan Stanley | Maintains | Underweight→Underweight |
| 2022-08-15 | Morgan Stanley | Maintains | Underweight→Underweight |
| 2022-03-02 | JP Morgan | Maintains | Neutral→Neutral |
| 2022-03-01 | SVB Leerink | Maintains | Market Perform→Market Perform |
Wall Street analysts have recently issued updated ratings on Atea Pharmaceuticals, Inc. (AVIR) stock. Of the recent 23 rating actions, 1 were upgrades and 5 were downgrades. 4 analysts currently cover AVIR.
Analyst Recommendation Trends
AVIR analyst recommendation trends show increasing buy-side sentiment over the past 6 months. Buy rating actions changed from 0 to 1 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$68M
↑ 1089.5% YoY
Revenue Next Year
$7M
↓ 89.6% YoY
EPS This Year
$-1.80
EPS Next Year
$-1.73
↓ 4.4% YoY
EPS ForecastReported vs Estimated
Analysts forecast AVIR EPS of $-1.80 for the current fiscal year, based on estimates from 3 analysts. The AVIR revenue forecast is $68M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The AVIR stock forecast is supported by two independent data sources: analyst consensus ratings from 4 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus AVIR price target is $10.00 (+130.9% upside), with an analyst consensus of Hold.
The AVIR short-term stock prediction for tomorrow is $4.23 (-2.36%). The AVIR stock prediction for 2030 projects a range of $5–$5.
Atea Pharmaceuticals, Inc. trades on NASDAQ under the ticker AVIR. The AVIR stock outlook for 2027 is broadly mixed, supported by a Hold consensus among 25% of covering analysts.
Frequently asked questions
AVIR forecast · 8 questionsAccording to 4 Wall Street analysts, the average 12-month AVIR price target is $10.00, with a high forecast of $10.00 and a low of $10.00. The median price target is shown in the chart above when available. This implies +130.9% potential upside from the current price of $4.33.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.